In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


KAHR Medical Ltd.

Latest From KAHR Medical Ltd.

Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties

IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.

Selected Start-Ups (5/06)

In Vivo briefly summarizes the technologies of these recently founded companies: Carbylan BioSurgery, KAHR Pharmaceuticals, Melior Discovery, Myomo, Nanonucleant, Pelican Life Sciences.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • KAHR Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • KAHR Medical Ltd.
  • Senior Management
  • Noam Shani, PhD, CEO
  • Contact Info
  • KAHR Medical Ltd.
    Phone: (972) 4 629 2112
    Kiryat Hadassah
    PO Box 12000
    Jerusalem, 91120